Subscribe to RSS
Download PDF
DOI: 10.1055/s-0040-1713946
Perception of Medication-related Osteonecrosis of the Jaws among Iraqi Medical Specialists
Authors
Funding None.
Abstract
Objective Osteonecrosis of the jaws is the adverse effect of antiresorptive and antiangiogenic agents, which is termed as medication-related osteonecrosis of the jaws (MRONJ). This complication, which is prominent and growing, is seen in the oral and maxillofacial region. This cross-sectional survey aimed to evaluate MRONJ awareness among Iraqi medical specialists.
Materials and Methods A questionnaire-based survey was performed on medical specialists practicing general surgery, urology, orthopedics, rheumatology, and oncology. The questionnaire consisted of four questions regarding drug prescription, patients’ preparation before drug administration, in addition to awareness and knowledge about MRONJ.
Results Among 132 specialists, 57% did not prescribe such drugs. A significant difference existed among groups regarding dental referral, and MRONJ awareness and knowledge. The highest rates were seen in the oncologist group.
Conclusions Improvement of MRONJ perception and knowledge among medical specialists, besides implementation of dental referral, are essential in the prevention, diagnosis and treatment of MRONJ.
Keywords
perception - awareness - medication-related osteonecrosis of the jaws (MRONJ) - questionnaire - specialistsPublication History
Article published online:
01 October 2021
© 2020. European Dental Research and Biomaterials Journal. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011; 49 (01) 71-76
- 2 Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352 (02) 154-164
- 3 Becorpi A, Sisti G, Sorbi F, Malosso ER, Guaschino S. Management options of breast cancer related osteoporosis. Clin Cases Miner Bone Metab 2014; 11 (02) 110-113
- 4 Sheets CF. All Cancers Excluding NonMelanoma Skin Cancer. International Agency for Research on Cancer 2016, World Health Organization. Available at: http://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-29.pdf. Accessed May 20, 2020
- 5 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61 (09) 1115-1117
- 6 Leite AF, Figueiredo PT, Melo NS. et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102 (01) 14-21
- 7 Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 2005; 136 (12) 1675-1681
- 8 Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62 (05) 527-534
- 9 Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98 (03) 259-260
- 10 Wooltorton E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. AJ 2005; 172 (13) 1684
- 11 Papapoulos S, Chapurlat R, Libanati C. et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27 (03) 694-701
- 12 Christodoulou C, Pervena A, Klouvas G. et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76 (03) 209-211
- 13 Ruggiero SL, Dodson TB, Fantasia J. et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg 2014; 72 (10) 1938-1956
- 14 Faculty of General Dental Practice. National study on avascular necrosis of the jaws. 2012
- 15 Lee JK, Kim KW, Choi JY. et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013; 39 (01) 9-13
- 16 Sturrock A, Preshaw PM, Hayes C, Wilkes S. Attitudes and perceptions of GPs and community pharmacists towards their role in the prevention of bisphosphonate-related osteonecrosis of the jaw: a qualitative study in the North East of England. BMJ Open 2017; 7 (09) e016047
- 17 Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health 2016; 16 (01) 92
- 18 Alkhader M, Alrashdan MS, Khader Y. Usefulness of measuring radiographic density of axis vertebra in patients at risk of osteoporosis: A cone-beam computed tomography study. Eur J Dent 2018; 12 (04) 496-501
- 19 Alkhader M, Aldawoodyeh A, Abdo N. Usefulness of measuring bone density of mandibular condyle in patients at risk of osteoporosis: A cone beam computed tomography study. Eur J Dent 2018; 12 (03) 363-368
- 20 Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F. Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 2015; 42 (10) 922-932
- 21 Diniz-Freitas M, Limeres J. Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review. Med Oral Patol Oral Cir Bucal 2016; 21 (02) e250-e259
- 22 Khan AA, Morrison A, Hanley DA. et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30 (01) 3-23
- 23 Bagán J, Blade J, Cozar JM. et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 2007; 12 (04) E336-E340
- 24 Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg 2009; 67 (05) , Suppl) 2-12
- 25 Al-Samman AA, Al-Ani RS. Across-sectional survey on medication-related osteonecrosis of the jaws’ knowledge and awareness in a sample of dental society. J Craniomaxillofac Surg 2019; 47 (06) 926-931
- 26 Al-Maweri SA, Alshammari MN, Alharbi AR. et al. Knowledge and opinions of saudi dentists regarding dental treatment of patients undergoing bisphosphonates. Eur J Dent 2020; 14 (01) 144-151
- 27 Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J 2011; 32 (08) 830-835
- 28 Sentürk MF, Cimen E, Tuzuner Oncul AM, Cambazoglu M. Oncologists awareness about bisphosphonate related osteonecrosis of the jaws. J Pak Med Assoc 2016; 66 (07) 880-883
- 29 Taguchi A, Shiraki M, Sugimoto T, Ohta H, Soen S. Japan Osteoporosis Society. Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin 2016; 32 (07) 1261-1268
- 30 Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009; 21 (04) 363-368
- 31 Migliorati CA, Mattos K, Palazzolo MJ. How patients’ lack of knowledge about oral bisphosphonates can interfere with medical and dental care. J Am Dent Assoc 2010; 141 (05) 562-566